Switching from Twice-Daily NPH to Lantus and Lispro
For a patient on NPH 25 U before breakfast and 25 U before dinner (total 50 U/day), switch to insulin glargine (Lantus) 40 U once daily at bedtime plus insulin lispro 4 U before each meal, then titrate based on glucose monitoring.
Conversion Algorithm
Step 1: Calculate Basal Insulin Dose
- Current total NPH dose: 50 U/day
- Initial glargine dose = 80% of total NPH dose 1, 2, 1
- Starting glargine: 40 U once daily at bedtime
This 20% dose reduction is critical because:
- Glargine has a more predictable, peakless profile compared to NPH
- Reduces initial hypoglycemia risk during the transition
- Allows for safe upward titration
Step 2: Add Prandial Insulin
- Start lispro at 4 U before each meal (breakfast, lunch, dinner) 1
- Alternative calculation: 10% of the reduced NPH dose = 4 U per meal
- This provides mealtime coverage that NPH alone cannot adequately address
Step 3: Titration Strategy
For Glargine (Basal):
- Set fasting plasma glucose target per individualized goals (typically 4.4-7.2 mmol/L or 80-130 mg/dL)
- Increase by 2 units every 3 days until fasting target achieved 1
- For hypoglycemia: reduce dose by 10-20% 1
For Lispro (Prandial):
- Increase by 1-2 units or 10-15% twice weekly based on pre-meal and 2-hour postprandial glucose 1, 2
- Target postprandial glucose typically <10 mmol/L (180 mg/dL)
Key Clinical Advantages
This switch offers several benefits supported by FDA labeling and clinical evidence:
- Reduced nocturnal hypoglycemia: Glargine's flat pharmacokinetic profile eliminates NPH's peak effect that commonly causes nighttime lows 3, 4
- Improved fasting glucose control: Once-daily glargine provides more consistent 24-hour basal coverage 3
- Better postprandial control: Rapid-acting lispro matches meal-related glucose excursions more physiologically than regular insulin 4, 5
- Simplified regimen: Three injections (glargine once + lispro three times) versus four NPH injections reduces complexity 5, 6
Critical Pitfalls to Avoid
Do not convert unit-for-unit: The 20% dose reduction is essential. Converting 50 U NPH to 50 U glargine significantly increases hypoglycemia risk, particularly in the first 4 weeks 7.
Timing matters: Administer glargine at bedtime initially. While glargine can be given at any consistent time of day 3, bedtime dosing during conversion minimizes fasting hyperglycemia while the patient adjusts 3.
Monitor closely in first month: Hypoglycemia risk is highest in the first 4 weeks after switching 7. Patients need clear instructions on recognizing and treating hypoglycemia, with glucagon prescription consideration 1.
Avoid mixing insulins: Never mix glargine with any other insulin in the same syringe 7. Use separate syringes for glargine and lispro.
Expected Outcomes
Based on clinical trial data comparing glargine/lispro to NPH regimens 3:
- Similar or improved HbA1c (typically 0.3-0.5% reduction)
- 44% reduction in nocturnal hypoglycemia episodes 4
- Improved fasting blood glucose (20-30 mg/dL reduction)
- Minimal weight change
The 2025 ADA Standards of Care explicitly support this basal-bolus intensification strategy when transitioning from twice-daily NPH, emphasizing the 80% dose conversion rule and systematic titration approach 1.